AEMD stock: buy or sell?
July 15th, 2019
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide.
Should I buy AEMD stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Aethlon Medical stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Aethlon Medical stock a buy?
Financial institutions and banks publish stock ratings everyday.Unfortunately, we couldn't detect any rating for AEMD stock for the last month.
AEMD stock analysis
Aethlon Medical ended today at $0.31 and plummed a scary -6.06%.
Aethlon Medical shares plummed -6.06% to $0.31 today. AEMD shows a short term strength with several rising tops and rising bottoms. In the very short term, on Wednesday it marked a new bottom at $0.32 that should act a support if Aethlon Medical starts a trading flat base in the range of $0.32 - $0.60 If Aethlon Medical breakouts over $0.60 with average or higher volume, this would be a clear signal that the uptrend resumes.
Shares of Aethlon Medical collapsed a scary -6.06% this week. Late June AEMD boosted a cool 5.41% in just one week.
Since mid February, when AEMD stock price broke down the 40-weeks moving avarage line, it slid $-1.05 per share (-77.21%). Stocks below the 40-weeks moving average line are usually not recommended for average traders.
AEMD stock price history
AEMD IPO was on February 11th, 2002 at $65.00 per share1. Since then, AEMD stock declined a -99.50%, with a yearly average of -5.90%.
1: Adjusted price after possible price splits or reverse-splits.
AEMD stock historical price chart
AEMD stock reached 52-week highs on November at $1.74, and all-time highs 2004-03-09 with a price of 212.5.
AEMD stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' AEMD stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price target for Aethlon Medical stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Aethlon Medical presented its financial report, posting an astounding gain for the Earnings per Share (EPS) ratio. Analyst expected $-0.07 per share, but Aethlon Medical posted $-0.11.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Aethlon Medical annual sales collapsed a chilling -61.84% to $0.15 million USD from $0.39 marked in 2017. Likewise, its earnings margin (compared to revenues) plunged to -3,795.86%, that is $-5.68 million. Aethlon Medical fiscal year ends in March, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Aethlon Medical TTM sales up to December 2018 were $0.22 and income $-5.87 M USD. When comparing this TTM figures with the last reported annuality, we can review Aethlon Medical business evolution since March 2018: Annual sales up to December, compared to lastest yearly report, boosted an amazing 50.00%. Regarding profit margin, Aethlon Medical climbed 1,179.77% to -3,795.86%
|2013||$1.23 M||-||$-4.89 M-397.6%||-|
|2014||$1.62 M||31.71%||$-13.36 M-824.7%||173.21%|
|2015||$0.76 M||-52.94%||$-6.80 M-891.5%||-49.12%|
|2016||$0.89 M||16.28%||$-4.87 M-549.6%||-28.32%|
|2017||$0.39 M||-55.78%||$-7.28 M-1855.8%||49.34%|
|2018||$0.15 M||-61.84%||$-5.68 M-3795.9%||-21.94%|
|TTM||$0.22 M||50.00%||$-5.87 M-2616.1%||3.38%|
Quarterly financial resultsReported quarter earnings marked $-2.01 million with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Aethlon Medical sales marked a dreadful loss and plunged a -100.00%. Looking back to recent quarterly results, Aethlon Medical posted 2 negative quarters in a row.
|2017-Q4||$0.07 M||-||$-1.22 M-1624.1%||-|
|2018-Q1||$0.07 M||0.00%||$-1.32 M-1762.9%||8.55%|
|2018-Q2||$0.15 M||100.00%||$-1.15 M-766.1%||-13.09%|
Aethlon Medical ownershipWhen you are planning to buy a stock, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Aethlon Medical, 6.64% of all outstanding shares are owned by its staff.
In case of Aethlon Medical stock, 14.95% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AEMD stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Aethlon Medical:
|Market cap||$5.2 M||$1.1 B||$16.2 M||$7.8 B||$3.2 B|
|Total shares||16.7 M||54.5 M||8.3 M||156.8 M||24.2 M|
|Float shares||17.7 M||27.1 M||6.8 M||103.8 M||23.9 M|
|- Institutional holdings (%)||14.9%||50.2%||12.3%||68.7%||101.1%|
|- Insider holdings (%)||6.6%||46.2%||28.6%||34.4%||1.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Monday, July 15th, 2019|
|Day range||$0.30 - $0.34|
|Average true range||$0.05|
|50d mov avg||$0.41|
|100d mov avg||$0.66|
|200d mov avg||$0.95|
Aethlon Medical performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Aethlon Medical performance to Accelerate Diagnostics, Bioanalytical Systems, Bruker, Coherent, Inovio Pharmaceuticals, Pacific Biosciences of California and PerkinElmer: